

Lawrence J Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5695646/publications.pdf>

Version: 2024-02-01

19
papers

370
citations

759233

12
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

645
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4058-4084.	6.4	1
2	A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, JPET-AR-2020-000370.	2.5	7
3	Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1605-1612.	2.8	3
4	Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 87-101.	5.0	32
5	Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 67-73.	2.8	6
6	Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 446-451.	2.8	9
7	Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 946-979.	6.4	19
8	Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 89-93.	2.8	12
9	Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 17-22.	2.8	13
10	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7168-7188.	6.4	22
11	Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. <i>Oncotarget</i> , 2018, 9, 16996-17013.	1.8	7
12	CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1377-1392.	4.1	31
13	Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects. <i>Neuron</i> , 2015, 85, 1305-1318.	8.1	57
14	Discovery of novel N-aryl piperazine CXCR4 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4950-4955.	2.2	19
15	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 753-757.	2.8	37
16	Structural analysis of CXCR4 " Antagonist interactions using saturation-transfer double-difference NMR. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 28-32.	2.1	12
17	Anti-HIV Small-Molecule Binding in the Peptide Subpocket of the CXCR4:CVX15 Crystal Structure. <i>ChemBioChem</i> , 2014, 15, 1614-1620.	2.6	23
18	Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1025-1030.	2.8	53

#	ARTICLE	IF	CITATIONS
19	Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents. Drug Development Research, 2011, 72, 598-602.	2.9	7